Git for SAS Programmers: Version Control in a GxP World
Why filename-versioned SAS programs are an audit-trail liability, the minimum Git vocabulary a clinical programmer needs, and how branch-per-output maps to QC.
Writing / Research & practice
Notes from the work.
Notes on LLM agents, clinical trial programming automation, and CDISC data standards — extended companions to my published research.
Browse by section, or search titles, descriptions and tags.
No results. Try a broader keyword, or clear the search to browse all sections.
Pipeline as Code: Automating the SDTM-to-ADaM-to-TLF Chain
How to turn the SDTM-to-ADaM-to-TLF chain into pipeline as code: explicit dependencies, pinned environments, hash-verified outputs, and stage-level failure isolation.
Becoming a Clinical Statistical Programmer in 2026: A Realistic Guide
What the job is, who gets hired, and how to train for it: a realistic 2026 guide to becoming a clinical statistical programmer, from SAS base to AI-assisted practice.
▶ video
The 2026 CDISC AI Challenge: Winners, Open Code, and a Synthetic ADaM Showdown
The 2026 CDISC AI Innovation Challenge winners present today in Denver. None published code — except one adjacent R package. We read synadam's source and compare it to our own synthetic ADaM pipeline.
Pharma Daily — October 5, 2026
One pipeline, five first-hand sources: 3 deals, 0 FDA approvals and 12 upcoming readouts, collected and charted without an LLM.
▶ video
Clinical R in Practice: The Open-Source Stack in Pharma
A 15-part series on R in pharma: pharmaverse ADaM, ARD tables, risk-based validation, targets pipelines, GxP Shiny, LLM agents — collected into a free bilingual book.
▶ video
Building ADaM with admiral: The LEGO Method
A complete ADaM derivation built from composable bricks: the derive_* mental model, ADSL and BDS patterns, and why company templates sit on top of admiral instead of replacing it.
▶ video
ARD: Analysis Results Data, and Why Tables Are Becoming Data
ARD turns tables from pixels into data — machine-reviewable, traceable, reusable. How the cards standard works, how gtsummary speaks it natively, and why reviewers will eventually ask for it.
▶ video
Agents and MCP in the R Clinical Stack
From chat to autonomous workflow: how the Model Context Protocol standardizes what tools agents may touch, what an agent-native clinical pipeline looks like, and the guardrails that keep autonomy auditable.
▶ video
From SDTM to Submission: The Clinical Data Flow, End to End
One map of every dataset, standard, and hand-off between the clinic and the regulator — SDTM, ADaM, define.xml, TLFs, and the submission package — and where R now sits at each stage.
▶ video
The Next Five Years of Clinical Data Science
The series compressed into one argument: standards absorbing tooling, tooling absorbing validation, validation absorbing AI — where the field goes, and the book this series becomes.
▶ video
rtables vs gt/gtsummary vs flextable: A Regulatory Showdown
One adverse-event table built three ways — the structural differences, the validation story of each framework, and a decision tree for which framework earns which role.
▶ video
Shiny in GxP: From rhino to a Validation File
The complete path for a clinical Shiny app: rhino structure, shinytest2 suites, secure backends, async patterns, and the validation evidence file that lets QA sign.
▶ video
LLMs Writing Trial Code: Production Cases, Real Limits
AI pair programmers for ADaM, LLM-assisted tables, QC drafting — the production case ledger from 2024-2026, and the exact wall each case hit when the rubber met validation.
▶ video
Metadata-Driven Development: metacore to xportr
Spec as code: how metacore, metatools, and xportr turn your define metadata into checks, labels, and transport files — killing inconsistency at the source instead of in QC.
▶ video
From Natural Language to CDISC Datasets
NL-to-CDISC generation, LLM-built analysis apps, auto slide decks — how close is the fully automatic submission, and which bottleneck is regulatory rather than technical?
▶ video
The Pharmaverse Ecosystem Map: Who Builds What, and Why
admiral, tern, teal, metacore, xportr — who builds which package, how they interlock, who governs them, and how a company or a solo programmer enters the ecosystem.
▶ video
Quarto for Clinical Study Reports
Parameterized CSR automation: branded documents, multi-study templating, the SAS engine for legacy code, and where auto-generated TLFs flow into review-ready reports.
▶ video
Risk-Based R Validation: Open Source Under Inspection
The R Validation Hub method, hands-on: risk dimensions, the public risk-assessment app, package qualification records, and what an inspector actually asks for when your stack is open source.
▶ video
The SAS-to-R Ledger: What Migrations Actually Cost
What large pharma migrations really cost — the training trap, the dual-run tax, the retraining ledger — and the ROI logic that survives an audit committee.
▶ video
targets Pipelines: Reproducible Clinical Analyses
Incremental compute, crew parallelism, frozen environments — a pipeline that re-runs in minutes, replays exactly a year later, and answers an inspector by existing.
▶ video
Validation as a Release Gate: Building a GxP Governance Layer for Shiny at Kardigan
How I designed the governance and validation layer for ClinVista, an internal Shiny data-review platform — and why it survived the decision to replace the platform itself.
▶ video
Free TFL Mock Shell Generator: A Practical Walkthrough
Build clinical TFL mock shells, review variable bindings, and export documents and SAS/R program scaffolds with a free browser tool and a practical walkthrough.
▶ video
Pharma Daily — September 17, 2026
One pipeline, five first-hand sources: 32 deals, 25 FDA approvals and 12 upcoming readouts, collected and charted without an LLM.
▶ video
Pharma Daily — September 9, 2026
Sep 8–9: 17 deal events, 0 FDA approvals, 12 queued readouts; Novartis's $12B Avidity bet hits a Phase 3 miss and Monte Rosa signs a $2.1B license.
▶ video
Novartis-Avidity at $12B: One Filing, One Win, One Miss
Six months after closing the $72/share Avidity buy: del-zota sits under FDA priority review, del-brax won Phase 1/2, and del-desiran failed HARBOR — NVS fell 13.9%.
▶ video
Pharma Daily — September 8, 2026
Sep 7–8: $14.6B in disclosed totals, zero FDA approvals, and Novartis's $12B Avidity buyout's lead asset fails Phase 3. Monte Rosa licenses VAV1 degraders to Novartis.
▶ video
Ivonescimab Clears OS vs Keytruda; the Hazard Ratio Waits for WCLC
HARMONi-2's OS win over pembrolizumab is real but detail-light: SMMT +17.3% on 2.7x volume, Akeso +15.3% in two sessions — and the HR itself lands at WCLC this month.
ADTTE and Time-to-Event: Programming the ADaM Analysis Dataset
ADTTE step by step: event and censoring definitions from the SAP, the censoring date cascade, CNSR semantics, partial dates at the event, and QC listings per subject.
▶ video
Pharma Daily — September 7, 2026
Sep 6–7: zero deals, zero FDA approvals, and 12 Phase 2/3 readouts due within 90 days. The calendar, not the tape, is the story.
AgomAb's $200M IPO: An 85% Rally With No Data Behind It
AgomAb priced $200M at the midpoint in February, broke 8.4% on debut, fell to a −39.9% close by June, then rallied 85% on no data — now −1.4% vs offer as of Sep 4.
▶ video
Aktis's $318M IPO: Lilly Took a Third, and the Tape Followed
Aktis priced 2026's first biotech IPO at the top of range with Eli Lilly buying $100M in the deal; the stock is +50% by September. The anchor playbook the class repeated.
Alamar's $220M IPO: The Tools Company the Bifurcation Didn't Touch
Alamar upsized 20% to $219.9M with the shoe, popped +29.4% on debut, and trades +81.2% vs offer — a proteomics tools story priced on revenue, not trial risk.
Apnimed's $220.8M IPO: An NDA-Stage Bet the Tape Keeps Rewarding
Apnimed upsized 20% to $192M at the top of range, popped +56.3% on debut, and trades +71.6% vs offer — with an FDA decision on its sleep-apnea pill due Feb 28, 2027.
Attovia's $289M IPO: Phase 1 Itch Data the Tape Paid For
Attovia priced an upsized $289M IPO at the $17 top of range on August 4, popped +28.8%, and never closed below offer — Phase 1b itch data, runway into 2030.
▶ video
Avalyn's $345M IPO: The Reformulation Play That Keeps Climbing
Avalyn upsized 41% to $300M at the top of range, popped +63.8%, and doubled by September on enrollment execution — with inhaled pirfenidone data due H2 2027.
BlossomHill's $150M IPO: Early-Stage, and the Tape Paid Anyway
BlossomHill upsized to $150M at $16.00 on August 6, 2026, traded flat on debut, then ground to +37.6% by the September 4 close on Phase 1 EGFR data and a dated path.
▶ video
Braveheart's $382.5M IPO: Hengrui NewCo #2 Holds Its Pop
Braveheart priced $382.5M above range for one Hengrui-in-licensed HCM drug, popped +65.6%, and holds +48.6% a month in — where Kailera round-tripped. The NewCo anatomy.
▶ video
Eikon's $381M IPO: Upsized at the Top, Down 40% Since
Eikon upsized to $381M at the top of range and broke −16.7% on debut, with no negative catalyst since. The class's clearest platform discount — and its H2 2026 binary.
▶ video
Generate's $400M IPO: The Worst Debut of 2026 Climbs Back
Generate priced $400M at range midpoint, fell −20.9% on debut — 2026's worst first day — and fought back above water by September on Phase 3 execution.
▶ video
Hemab's $347M IPO: +88% Debut, Then the Data Kept Coming
Hemab upsized 42% to $347M, popped +88.9%, then climbed on ISTH data and an FDA-endorsed Phase 3 path in Glanzmann thrombasthenia. A +147% tape, anatomized.
▶ video
Kailera's $625M IPO: The Record That Gave Back the Pop
Kailera priced a then-record $625M at the top of range, popped +62.5%, and round-tripped to +1.4% by September. The Hengrui in-license anatomy and what reprices it.
Kardigan's $460M IPO: Three In-Licensed Heart Drugs, a Modest Premium
Kardigan priced 25M shares at the $16 top of range, popped +37.5% on debut, and holds +30.3% vs offer as of Sep 4 — with all three cardiac readouts guided to H1 2027.
Latigo's $397M IPO: A Phase 3-Ready Pain Bet the Tape Bought Early
Latigo priced $345.6M at the top of range on Aug 6, 2026 — $397.4M after a full greenshoe — behind a Phase 3-ready oral NaV1.8 pain drug; +28.0% vs offer as of Sep 4.
Odyssey's Second-Attempt IPO: Broke on Debut, Up 59.8% by September
Odyssey priced an upsized $279M IPO at the top of range on May 7, broke 8.8% on debut, then re-rated +59.8% by the Sep 4 close on two earnings prints.
▶ video
Parabilis's Record IPO: The Platform That Trades Like a Product
Parabilis priced a record $670M biotech IPO above range after two upsizes; twelve weeks later the tape pays for one desmoid-tumor asset, not the Helicon platform.
Scribe's $148M IPO: The Platform Story the Tape Actually Paid For
Scribe priced an upsized IPO at the $15 top on Jul 23, closed at $148M with a full shoe plus a $7.5M Sanofi placement, and trades +91.1% vs offer.
Seaport's $260M IPO: PureTech's Glyph Bet Grinds Back Above Water
Seaport upsized 20% to $254.9M at the top of range, closed up 10.2% on debut, and trades +38.1% vs offer as of Sep 4 — on prodrug chemistry, not platform adjectives.
▶ video
SpyGlass's $172.5M IPO: Small Check, Steady Tape
SpyGlass priced $172.5M at midpoint with no upsize, popped +65%, and holds +81% by September on a 505(b)(2) glaucoma implant with two Phase 3s enrolling.
▶ video
Veradermics' $295M IPO: A +479% Run Built on Two Data Days
Veradermics priced $295M at $17, popped +122%, then two pivotal readouts and a $442M follow-on at $100 took it to +479% of offer. The class's best tape.
Vogenx's $93M IPO: The Class's Smallest Deal More Than Doubled
Vogenx raised $93.4M all-in at $13 — the smallest 2026 biotech IPO — then ran +144.1% by the September 4 close with zero post-IPO disclosures. Float, not data.
▶ video
Pharma Daily — September 5, 2026
Sep 4–5: Menarini/Gan & Lee $771M GLP-1 deal, NeuShen $80M financing, Novartis Lp(a) miss — China-originated assets took 100% of disclosed dollars.
▶ video
The New Biotech IPO Class: Bigger, Later-Stage, and Judged Harder
21 US biotech IPOs raised ~$6.5B in 2026 through Aug 11 — median check $295M, 18 of 21 above offer as of Aug 28. What the class tells practitioners.
▶ video
Pharma Daily — September 4, 2026
Sep 3–4: GSK-Hutchmed $110M upfront license, Medicus $1B ADC deal, ivonescimab Phase 3 OS win — China-originated assets dominated both deal flow and the tape.
Top 20 Pharma by Market Cap, Q3 2026: A $5.1 Trillion Table
As of Sep 4, 2026, the 20 largest pharma companies total $5.12T; Lilly alone is 20% of the table, Novo sits at #9, and WuXi AppTec leads YTD movers at +90%.
▶ video ✎ interactive lesson
ADaM OCCDS Explained: Programming ADAE with Treatment Flags
ADAE from the OCCDS side: one row per event, the AE-to-ADSL merge, treatment-emergent flags driven by TRT01SDT, serious flags, and the QC defects reviewers catch.
▶ video ✎ interactive lesson
ADaM BDS Structure: Building ADLB and ADVS Step by Step
The BDS skeleton behind ADaM analysis datasets: PARAM/PARAMCD/AVAL, baseline flags, change from baseline, and how ADVS and ADLB are built visit by visit.
SDTM AE Domain Mapping: A Worked Example from Raw EDC Data
A worked SDTM AE domain mapping example: MedDRA coding, serious flags, partial ISO dates, AESEQ derivation, SUPPAE, and CORE validation triage from a mock raw extract.
How to Write an SDTM Mapping Specification (Walkthrough)
How to write an SDTM mapping specification: column anatomy, a row-by-row VS domain walk, hygiene rules, and how specs become define-XML and machine-usable code.
SDTM Domain Basics: The Model Every Clinical Programmer Must Know
SDTM domains explained: domain classes, the topic-timing-qualifier variable pattern, USUBJID, controlled terminology, SUPPQUAL, and a day-one reading order.
▶ video ✎ interactive lesson
ADSL Derivation Walkthrough: TRT01SDT, Flags, and the Merge Traps
How ADSL is built: deriving treatment dates and population flags from DM/EX/DS/SV, the one-row-per-subject rule, and the QC checks that catch real discrepancies.
▶ video ✎ interactive lesson
The Clinical SP Bootcamp: A Learning Path from Raw Data to TLF
A systematic path into clinical statistical programming: CDISC fundamentals, modern SCE workflow, and where AI agents fit — every part with runnable takeaways.
▶ video ✎ interactive lesson
Clinical SAS Interview Questions: What Actually Gets Asked
How clinical SAS interviews actually work: four rounds from SAS mechanics to GxP habits, real-format questions, and the signals strong answers contain.
▶ video ✎ interactive lesson
Statistical Computing Environments: From SAS VM to Cloud SCE
What a statistical computing environment is for in clinical trials, why desktop SAS and shared drives failed audits, and how cloud SCE workflow changes day one.
▶ video ✎ interactive lesson
From Mock Shell to RTF: How Clinical TLF Outputs Actually Ship
How clinical TLF outputs ship: reading mock shells, PROC REPORT tables and listings, RTF conventions, and the four-pass QC order that catches defects cheapest first.
AI Coding Assistants for Clinical Programmers: What Works in GxP
Where ChatGPT, Claude, and Copilot genuinely save time in SAS and R clinical programming, where they fail, and how to use them inside auditable GxP workflows.
#ai-coding-assistants#sas-programming#gxp#clinical-programming#llm-tools
CDISC CORE Explained: Open-Source Validation for SDTM/ADaM Programmers
CDISC CORE is a free, open-source rule engine for SDTM and ADaM validation. How its YAML rules work, how to run it, and where rule-based checking stops.
LLM Agents in Clinical Trials: What's Real Beyond the Demos
How to tell demo-ware from deployable agentic AI in clinical trials: determinism, audit trails, 21 CFR Part 11, constrained architectures, and vendor questions.
#llm-agents#clinical-trials#gxp#audit-trail#agent-architecture
LLMs in Clinical Statistical Programming: Proven vs Hype (2026)
A tiered survey of LLM evidence in clinical trial statistical programming: benchmarked results, promising single-team studies, vendor hype, and open gaps for 2026–2027.
#llm#clinical-trials#statistical-programming#survey#benchmarks#gxp
One Number That Explains Where Rule-Based Validation Stops
69.7% of oncology CORE rules port cleanly to a graph constraint language. The 30% that don't are exactly where the dangerous errors live.
Temperature 0 Doesn't Buy You Reproducibility
Setting temperature to zero feels like determinism. It isn't — and in GxP work the difference will find you during an audit, not during development.
SAS to R Migration in Clinical Programming: A Practical Field Guide
Why pharma is moving from SAS to R, what breaks in practice (procedures, XPT files, QC), and how to migrate a validated macro library without a rewrite.
#sas-to-r#pharmaverse#admiral#clinical-programming#xpt#validation
The Contradictions Your Validator Can't See
Rule-based SDTM validators structurally miss cross-domain contradictions. SHACL-SPARQL graph constraints plus a deterministic agent layer catch all 20 archetypes.
Double Programming Without the Duplication: AI-Generated QC Code
Independent QC re-programming costs 30–50% of clinical programming effort. An AI framework matched 97.1–100% of variables while keeping independence intact.
Benchmarking RAG for Clinical TLF Templates: 1,999 Experiments
Five LLM generation methods benchmarked across 1,999 bootstrap experiments on ICH E3-conformant TLF templates: hybrid RAG with reranking beats direct prompting.
#rag#llm-benchmarking#tlf-templates#clinical-trials#r-code-generation
Why LLM Agents Fail at Regulated Programming — the Process-DAG Fix
Free-form agent loops break down in GxP clinical programming. Structuring the work as a typed process DAG makes LLM agents reliable, replayable, and auditable.
Five Years of Automation Evidence: Real Gains, Mostly Low Grades
A GRADE-rated review of 2020–2025 automation evidence in statistical programming: real gains, mostly Low to Very Low quality evidence.
#statistical-programming#automation#evidence-quality#clinical-trials
Modernizing a 558-Macro SAS Library Without Touching Validated Code
A bridge map, typed IR, and orchestrator wrap a legacy SAS TFL library unchanged — AI-ready JSON on day one, 80%+ cell-level parity, optional 92% code cut.
#sas#legacy-modernization#clinical-trials#llm-integration#statistical-programming
Thin MCP, Thick Skills: Five Layers for Clinical Programming Agents
ClinAgent splits clinical programming capability into five layers, keeping MCP tools stateless and packaging domain expertise as testable skills.
#llm-agents#mcp#clinical-trials#statistical-programming#agent-architecture
Synthetic ADaM That Survives a Join: Knowledge Graphs, LLMs, Faker
Schema-only synthetic ADaM generation plateaus at 0.45 overall quality; enriching schemas from protocol/SAP/CRF knowledge graphs plus templates reaches 0.70.
#synthetic-data#adam#knowledge-graphs#llm#statistical-programming
Fine-Tuning Llama 3.1 8B for admiral R Code: From 0.36 to 0.82
Base Llama 3.1 8B scores 0.36 on admiral code generation. LoRA fine-tuning plus knowledge-graph validation gets it to 0.82 — without sending data to an API.
Interactive explainer
From Raw Data to TLF: The Clinical Data Journey
How a messy EDC extract becomes a submission package — eight animated scenes covering SDTM mapping, SUPPQUAL, ADSL, BDS baseline and windowing, TLF production and QC, and Define-XML. Play it like a lecture, one beat at a time.
Interactive explainer
The Contradictions Your Validator Can't See
Why domain-scoped SDTM validators structurally miss cross-domain RECIST contradictions — seven scenes from one impossible response to the graph, the SHACL shapes, the deterministic agent, and the 20/20 scoreboard with its fine print.
Interactive explainer
Thin MCP, Thick Skills: Five Layers for Clinical Programming Agents
ClinAgent's five-layer stack — thin stateless MCP tools, thick testable skills, compliance infrastructure — traced through one tool call, the STUDY-A validation bench, and the study-specific failure mode. Seven scenes.
Latest
- 2026-10-06 Git for SAS Programmers: Version Control in a GxP World
- 2026-10-06 Pipeline as Code: Automating the SDTM-to-ADaM-to-TLF Chain
- 2026-10-06 Becoming a Clinical Statistical Programmer in 2026: A Realistic Guide
- 2026-10-05 The 2026 CDISC AI Challenge: Winners, Open Code, and a Synthetic ADaM Showdown
- 2026-10-05 Pharma Daily — October 5, 2026
Start here
The pieces that best represent what this blog is about.
Intro · ▶ video
Clinical R in Practice: The Open-Source Stack in Pharma
A 15-part series on R in pharma: pharmaverse ADaM, ARD tables, risk-based validation, targets pipelines, GxP Shiny, LLM agents — collected into a free bilingual book.
Intro · ▶ video ✎ interactive lesson
The Clinical SP Bootcamp: A Learning Path from Raw Data to TLF
A systematic path into clinical statistical programming: CDISC fundamentals, modern SCE workflow, and where AI agents fit — every part with runnable takeaways.
The Contradictions Your Validator Can't See
Rule-based SDTM validators structurally miss cross-domain contradictions. SHACL-SPARQL graph constraints plus a deterministic agent layer catch all 20 archetypes.
Double Programming Without the Duplication: AI-Generated QC Code
Independent QC re-programming costs 30–50% of clinical programming effort. An AI framework matched 97.1–100% of variables while keeping independence intact.
Research Deep-Dives
Extended companions to the published papers — methods, results, and honest limitations.
▶ video
The 2026 CDISC AI Challenge: Winners, Open Code, and a Synthetic ADaM Showdown
The 2026 CDISC AI Innovation Challenge winners present today in Denver. None published code — except one adjacent R package. We read synadam's source and compare it to our own synthetic ADaM pipeline.
▶ video
Validation as a Release Gate: Building a GxP Governance Layer for Shiny at Kardigan
How I designed the governance and validation layer for ClinVista, an internal Shiny data-review platform — and why it survived the decision to replace the platform itself.
The Contradictions Your Validator Can't See
Rule-based SDTM validators structurally miss cross-domain contradictions. SHACL-SPARQL graph constraints plus a deterministic agent layer catch all 20 archetypes.
Double Programming Without the Duplication: AI-Generated QC Code
Independent QC re-programming costs 30–50% of clinical programming effort. An AI framework matched 97.1–100% of variables while keeping independence intact.
Benchmarking RAG for Clinical TLF Templates: 1,999 Experiments
Five LLM generation methods benchmarked across 1,999 bootstrap experiments on ICH E3-conformant TLF templates: hybrid RAG with reranking beats direct prompting.
#rag#llm-benchmarking#tlf-templates#clinical-trials#r-code-generation
Why LLM Agents Fail at Regulated Programming — the Process-DAG Fix
Free-form agent loops break down in GxP clinical programming. Structuring the work as a typed process DAG makes LLM agents reliable, replayable, and auditable.
Five Years of Automation Evidence: Real Gains, Mostly Low Grades
A GRADE-rated review of 2020–2025 automation evidence in statistical programming: real gains, mostly Low to Very Low quality evidence.
#statistical-programming#automation#evidence-quality#clinical-trials
Modernizing a 558-Macro SAS Library Without Touching Validated Code
A bridge map, typed IR, and orchestrator wrap a legacy SAS TFL library unchanged — AI-ready JSON on day one, 80%+ cell-level parity, optional 92% code cut.
#sas#legacy-modernization#clinical-trials#llm-integration#statistical-programming
Thin MCP, Thick Skills: Five Layers for Clinical Programming Agents
ClinAgent splits clinical programming capability into five layers, keeping MCP tools stateless and packaging domain expertise as testable skills.
#llm-agents#mcp#clinical-trials#statistical-programming#agent-architecture
Synthetic ADaM That Survives a Join: Knowledge Graphs, LLMs, Faker
Schema-only synthetic ADaM generation plateaus at 0.45 overall quality; enriching schemas from protocol/SAP/CRF knowledge graphs plus templates reaches 0.70.
#synthetic-data#adam#knowledge-graphs#llm#statistical-programming
Fine-Tuning Llama 3.1 8B for admiral R Code: From 0.36 to 0.82
Base Llama 3.1 8B scores 0.36 on admiral code generation. LoRA fine-tuning plus knowledge-graph validation gets it to 0.82 — without sending data to an API.
Clinical SP Bootcamp
A systematic training series: fundamentals, modern SCE workflow, and the agentic way — from raw data to TLF delivery. Key parts ship a downloadable Claude skill. Every part pairs with an interactive lesson (✎ badge). Series DOI: 10.5281/zenodo.22233175.
Intro · ▶ video ✎ interactive lesson
The Clinical SP Bootcamp: A Learning Path from Raw Data to TLF
A systematic path into clinical statistical programming: CDISC fundamentals, modern SCE workflow, and where AI agents fit — every part with runnable takeaways.
Part 1 · ▶ video ✎ interactive lesson
Statistical Computing Environments: From SAS VM to Cloud SCE
What a statistical computing environment is for in clinical trials, why desktop SAS and shared drives failed audits, and how cloud SCE workflow changes day one.
Part 2 · ▶ video ✎ interactive lesson
ADSL Derivation Walkthrough: TRT01SDT, Flags, and the Merge Traps
How ADSL is built: deriving treatment dates and population flags from DM/EX/DS/SV, the one-row-per-subject rule, and the QC checks that catch real discrepancies.
Part 3 · ▶ video ✎ interactive lesson
From Mock Shell to RTF: How Clinical TLF Outputs Actually Ship
How clinical TLF outputs ship: reading mock shells, PROC REPORT tables and listings, RTF conventions, and the four-pass QC order that catches defects cheapest first.
Part 4 · ✎ interactive lesson
SDTM Domain Basics: The Model Every Clinical Programmer Must Know
SDTM domains explained: domain classes, the topic-timing-qualifier variable pattern, USUBJID, controlled terminology, SUPPQUAL, and a day-one reading order.
Part 5 · ✎ interactive lesson
SDTM AE Domain Mapping: A Worked Example from Raw EDC Data
A worked SDTM AE domain mapping example: MedDRA coding, serious flags, partial ISO dates, AESEQ derivation, SUPPAE, and CORE validation triage from a mock raw extract.
Part 6 · ✎ interactive lesson
How to Write an SDTM Mapping Specification (Walkthrough)
How to write an SDTM mapping specification: column anatomy, a row-by-row VS domain walk, hygiene rules, and how specs become define-XML and machine-usable code.
Part 7 · ▶ video ✎ interactive lesson
ADaM BDS Structure: Building ADLB and ADVS Step by Step
The BDS skeleton behind ADaM analysis datasets: PARAM/PARAMCD/AVAL, baseline flags, change from baseline, and how ADVS and ADLB are built visit by visit.
Part 8 · ▶ video ✎ interactive lesson
ADaM OCCDS Explained: Programming ADAE with Treatment Flags
ADAE from the OCCDS side: one row per event, the AE-to-ADSL merge, treatment-emergent flags driven by TRT01SDT, serious flags, and the QC defects reviewers catch.
Part 9 · ✎ interactive lesson
ADTTE and Time-to-Event: Programming the ADaM Analysis Dataset
ADTTE step by step: event and censoring definitions from the SAP, the censoring date cascade, CNSR semantics, partial dates at the event, and QC listings per subject.
Part 10 · ▶ video ✎ interactive lesson
Clinical SAS Interview Questions: What Actually Gets Asked
How clinical SAS interviews actually work: four rounds from SAS mechanics to GxP habits, real-format questions, and the signals strong answers contain.
Part 11 · ✎ interactive lesson
Becoming a Clinical Statistical Programmer in 2026: A Realistic Guide
What the job is, who gets hired, and how to train for it: a realistic 2026 guide to becoming a clinical statistical programmer, from SAS base to AI-assisted practice.
Part 12 · ✎ interactive lesson
Git for SAS Programmers: Version Control in a GxP World
Why filename-versioned SAS programs are an audit-trail liability, the minimum Git vocabulary a clinical programmer needs, and how branch-per-output maps to QC.
Part 13 · ✎ interactive lesson
Pipeline as Code: Automating the SDTM-to-ADaM-to-TLF Chain
How to turn the SDTM-to-ADaM-to-TLF chain into pipeline as code: explicit dependencies, pinned environments, hash-verified outputs, and stage-level failure isolation.
Clinical R in Practice
The open-source stack behind regulated drug development: the pharmaverse ADaM toolchain, regulatory-grade tables and ARD, risk-based validation, reproducible pipelines, GxP Shiny, and where LLM agents honestly fit. The complete series is also a free companion book.
Intro · ▶ video
Clinical R in Practice: The Open-Source Stack in Pharma
A 15-part series on R in pharma: pharmaverse ADaM, ARD tables, risk-based validation, targets pipelines, GxP Shiny, LLM agents — collected into a free bilingual book.
Part 1 · ▶ video
From SDTM to Submission: The Clinical Data Flow, End to End
One map of every dataset, standard, and hand-off between the clinic and the regulator — SDTM, ADaM, define.xml, TLFs, and the submission package — and where R now sits at each stage.
Part 2 · ▶ video
The Pharmaverse Ecosystem Map: Who Builds What, and Why
admiral, tern, teal, metacore, xportr — who builds which package, how they interlock, who governs them, and how a company or a solo programmer enters the ecosystem.
Part 3 · ▶ video
The SAS-to-R Ledger: What Migrations Actually Cost
What large pharma migrations really cost — the training trap, the dual-run tax, the retraining ledger — and the ROI logic that survives an audit committee.
Part 4 · ▶ video
Building ADaM with admiral: The LEGO Method
A complete ADaM derivation built from composable bricks: the derive_* mental model, ADSL and BDS patterns, and why company templates sit on top of admiral instead of replacing it.
Part 5 · ▶ video
Metadata-Driven Development: metacore to xportr
Spec as code: how metacore, metatools, and xportr turn your define metadata into checks, labels, and transport files — killing inconsistency at the source instead of in QC.
Part 6 · ▶ video
rtables vs gt/gtsummary vs flextable: A Regulatory Showdown
One adverse-event table built three ways — the structural differences, the validation story of each framework, and a decision tree for which framework earns which role.
Part 7 · ▶ video
ARD: Analysis Results Data, and Why Tables Are Becoming Data
ARD turns tables from pixels into data — machine-reviewable, traceable, reusable. How the cards standard works, how gtsummary speaks it natively, and why reviewers will eventually ask for it.
Part 8 · ▶ video
Quarto for Clinical Study Reports
Parameterized CSR automation: branded documents, multi-study templating, the SAS engine for legacy code, and where auto-generated TLFs flow into review-ready reports.
Part 9 · ▶ video
Risk-Based R Validation: Open Source Under Inspection
The R Validation Hub method, hands-on: risk dimensions, the public risk-assessment app, package qualification records, and what an inspector actually asks for when your stack is open source.
Part 10 · ▶ video
targets Pipelines: Reproducible Clinical Analyses
Incremental compute, crew parallelism, frozen environments — a pipeline that re-runs in minutes, replays exactly a year later, and answers an inspector by existing.
Part 11 · ▶ video
Shiny in GxP: From rhino to a Validation File
The complete path for a clinical Shiny app: rhino structure, shinytest2 suites, secure backends, async patterns, and the validation evidence file that lets QA sign.
Part 12 · ▶ video
LLMs Writing Trial Code: Production Cases, Real Limits
AI pair programmers for ADaM, LLM-assisted tables, QC drafting — the production case ledger from 2024-2026, and the exact wall each case hit when the rubber met validation.
Part 13 · ▶ video
Agents and MCP in the R Clinical Stack
From chat to autonomous workflow: how the Model Context Protocol standardizes what tools agents may touch, what an agent-native clinical pipeline looks like, and the guardrails that keep autonomy auditable.
Part 14 · ▶ video
From Natural Language to CDISC Datasets
NL-to-CDISC generation, LLM-built analysis apps, auto slide decks — how close is the fully automatic submission, and which bottleneck is regulatory rather than technical?
Part 15 · ▶ video
The Next Five Years of Clinical Data Science
The series compressed into one argument: standards absorbing tooling, tooling absorbing validation, validation absorbing AI — where the field goes, and the book this series becomes.
Learning Center
The bootcamp as interactive lessons — scenes, checkpoint quizzes, hands-on practice, progress saved in your browser.
Open the Learning Center → 8 lines · 21 lessons All 21 lessons live. Each pairs with its bootcamp article, adds checkpoint quizzes and hands-on practice, and saves your progress locally.Field Guides & Hot Topics
Practical explainers on the tools and debates shaping clinical programming today.
AI Coding Assistants for Clinical Programmers: What Works in GxP
Where ChatGPT, Claude, and Copilot genuinely save time in SAS and R clinical programming, where they fail, and how to use them inside auditable GxP workflows.
#ai-coding-assistants#sas-programming#gxp#clinical-programming#llm-tools
CDISC CORE Explained: Open-Source Validation for SDTM/ADaM Programmers
CDISC CORE is a free, open-source rule engine for SDTM and ADaM validation. How its YAML rules work, how to run it, and where rule-based checking stops.
LLM Agents in Clinical Trials: What's Real Beyond the Demos
How to tell demo-ware from deployable agentic AI in clinical trials: determinism, audit trails, 21 CFR Part 11, constrained architectures, and vendor questions.
#llm-agents#clinical-trials#gxp#audit-trail#agent-architecture
SAS to R Migration in Clinical Programming: A Practical Field Guide
Why pharma is moving from SAS to R, what breaks in practice (procedures, XPT files, QC), and how to migrate a validated macro library without a rewrite.
#sas-to-r#pharmaverse#admiral#clinical-programming#xpt#validation
Interactive Explainers
Self-contained animated walkthroughs of the series' flagship topics — play them like a lecture, one beat at a time. All explainers →
2026-09-01 · 8 scenes · interactive
From Raw Data to TLF: The Clinical Data Journey
How a messy EDC extract becomes a submission package — eight animated scenes covering SDTM mapping, SUPPQUAL, ADSL, BDS baseline and windowing, TLF production and QC, and Define-XML. Play it like a lecture, one beat at a time.
2026-09-02 · 7 scenes · interactive
The Contradictions Your Validator Can't See
Why domain-scoped SDTM validators structurally miss cross-domain RECIST contradictions — seven scenes from one impossible response to the graph, the SHACL shapes, the deterministic agent, and the 20/20 scoreboard with its fine print.
2026-09-02 · 7 scenes · interactive
Thin MCP, Thick Skills: Five Layers for Clinical Programming Agents
ClinAgent's five-layer stack — thin stateless MCP tools, thick testable skills, compliance infrastructure — traced through one tool call, the STUDY-A validation bench, and the study-specific failure mode. Seven scenes.
State of the Field
Quarterly surveys of the evidence — what's proven, what's hype, with full references.
LLMs in Clinical Statistical Programming: Proven vs Hype (2026)
A tiered survey of LLM evidence in clinical trial statistical programming: benchmarked results, promising single-team studies, vendor hype, and open gaps for 2026–2027.
#llm#clinical-trials#statistical-programming#survey#benchmarks#gxp
Notes
Short, frequent observations — tools, papers, and field notes. Longer arguments live in the sections above.
▶ video
Free TFL Mock Shell Generator: A Practical Walkthrough
Build clinical TFL mock shells, review variable bindings, and export documents and SAS/R program scaffolds with a free browser tool and a practical walkthrough.
One Number That Explains Where Rule-Based Validation Stops
69.7% of oncology CORE rules port cleanly to a graph constraint language. The 30% that don't are exactly where the dangerous errors live.
Temperature 0 Doesn't Buy You Reproducibility
Setting temperature to zero feels like determinism. It isn't — and in GxP work the difference will find you during an audit, not during development.
Biotech IPO & Markets
IPO debuts and pharma market tables — pricing, first-day pops, and what the tape says afterwards. Slower-moving companions to the daily brief.
▶ video
Novartis-Avidity at $12B: One Filing, One Win, One Miss
Six months after closing the $72/share Avidity buy: del-zota sits under FDA priority review, del-brax won Phase 1/2, and del-desiran failed HARBOR — NVS fell 13.9%.
▶ video
Ivonescimab Clears OS vs Keytruda; the Hazard Ratio Waits for WCLC
HARMONi-2's OS win over pembrolizumab is real but detail-light: SMMT +17.3% on 2.7x volume, Akeso +15.3% in two sessions — and the HR itself lands at WCLC this month.
AgomAb's $200M IPO: An 85% Rally With No Data Behind It
AgomAb priced $200M at the midpoint in February, broke 8.4% on debut, fell to a −39.9% close by June, then rallied 85% on no data — now −1.4% vs offer as of Sep 4.
▶ video
Aktis's $318M IPO: Lilly Took a Third, and the Tape Followed
Aktis priced 2026's first biotech IPO at the top of range with Eli Lilly buying $100M in the deal; the stock is +50% by September. The anchor playbook the class repeated.
Alamar's $220M IPO: The Tools Company the Bifurcation Didn't Touch
Alamar upsized 20% to $219.9M with the shoe, popped +29.4% on debut, and trades +81.2% vs offer — a proteomics tools story priced on revenue, not trial risk.
Apnimed's $220.8M IPO: An NDA-Stage Bet the Tape Keeps Rewarding
Apnimed upsized 20% to $192M at the top of range, popped +56.3% on debut, and trades +71.6% vs offer — with an FDA decision on its sleep-apnea pill due Feb 28, 2027.
Attovia's $289M IPO: Phase 1 Itch Data the Tape Paid For
Attovia priced an upsized $289M IPO at the $17 top of range on August 4, popped +28.8%, and never closed below offer — Phase 1b itch data, runway into 2030.
▶ video
Avalyn's $345M IPO: The Reformulation Play That Keeps Climbing
Avalyn upsized 41% to $300M at the top of range, popped +63.8%, and doubled by September on enrollment execution — with inhaled pirfenidone data due H2 2027.
BlossomHill's $150M IPO: Early-Stage, and the Tape Paid Anyway
BlossomHill upsized to $150M at $16.00 on August 6, 2026, traded flat on debut, then ground to +37.6% by the September 4 close on Phase 1 EGFR data and a dated path.
▶ video
Braveheart's $382.5M IPO: Hengrui NewCo #2 Holds Its Pop
Braveheart priced $382.5M above range for one Hengrui-in-licensed HCM drug, popped +65.6%, and holds +48.6% a month in — where Kailera round-tripped. The NewCo anatomy.
▶ video
Eikon's $381M IPO: Upsized at the Top, Down 40% Since
Eikon upsized to $381M at the top of range and broke −16.7% on debut, with no negative catalyst since. The class's clearest platform discount — and its H2 2026 binary.
▶ video
Generate's $400M IPO: The Worst Debut of 2026 Climbs Back
Generate priced $400M at range midpoint, fell −20.9% on debut — 2026's worst first day — and fought back above water by September on Phase 3 execution.
▶ video
Hemab's $347M IPO: +88% Debut, Then the Data Kept Coming
Hemab upsized 42% to $347M, popped +88.9%, then climbed on ISTH data and an FDA-endorsed Phase 3 path in Glanzmann thrombasthenia. A +147% tape, anatomized.
▶ video
Kailera's $625M IPO: The Record That Gave Back the Pop
Kailera priced a then-record $625M at the top of range, popped +62.5%, and round-tripped to +1.4% by September. The Hengrui in-license anatomy and what reprices it.
Kardigan's $460M IPO: Three In-Licensed Heart Drugs, a Modest Premium
Kardigan priced 25M shares at the $16 top of range, popped +37.5% on debut, and holds +30.3% vs offer as of Sep 4 — with all three cardiac readouts guided to H1 2027.
Latigo's $397M IPO: A Phase 3-Ready Pain Bet the Tape Bought Early
Latigo priced $345.6M at the top of range on Aug 6, 2026 — $397.4M after a full greenshoe — behind a Phase 3-ready oral NaV1.8 pain drug; +28.0% vs offer as of Sep 4.
Odyssey's Second-Attempt IPO: Broke on Debut, Up 59.8% by September
Odyssey priced an upsized $279M IPO at the top of range on May 7, broke 8.8% on debut, then re-rated +59.8% by the Sep 4 close on two earnings prints.
▶ video
Parabilis's Record IPO: The Platform That Trades Like a Product
Parabilis priced a record $670M biotech IPO above range after two upsizes; twelve weeks later the tape pays for one desmoid-tumor asset, not the Helicon platform.
Scribe's $148M IPO: The Platform Story the Tape Actually Paid For
Scribe priced an upsized IPO at the $15 top on Jul 23, closed at $148M with a full shoe plus a $7.5M Sanofi placement, and trades +91.1% vs offer.
Seaport's $260M IPO: PureTech's Glyph Bet Grinds Back Above Water
Seaport upsized 20% to $254.9M at the top of range, closed up 10.2% on debut, and trades +38.1% vs offer as of Sep 4 — on prodrug chemistry, not platform adjectives.
▶ video
SpyGlass's $172.5M IPO: Small Check, Steady Tape
SpyGlass priced $172.5M at midpoint with no upsize, popped +65%, and holds +81% by September on a 505(b)(2) glaucoma implant with two Phase 3s enrolling.
▶ video
Veradermics' $295M IPO: A +479% Run Built on Two Data Days
Veradermics priced $295M at $17, popped +122%, then two pivotal readouts and a $442M follow-on at $100 took it to +479% of offer. The class's best tape.
Vogenx's $93M IPO: The Class's Smallest Deal More Than Doubled
Vogenx raised $93.4M all-in at $13 — the smallest 2026 biotech IPO — then ran +144.1% by the September 4 close with zero post-IPO disclosures. Float, not data.
▶ video
The New Biotech IPO Class: Bigger, Later-Stage, and Judged Harder
21 US biotech IPOs raised ~$6.5B in 2026 through Aug 11 — median check $295M, 18 of 21 above offer as of Aug 28. What the class tells practitioners.
Top 20 Pharma by Market Cap, Q3 2026: A $5.1 Trillion Table
As of Sep 4, 2026, the 20 largest pharma companies total $5.12T; Lilly alone is 20% of the table, Novo sits at #9, and WuXi AppTec leads YTD movers at +90%.
Pharma Daily
A daily pharma/biotech finance brief built from first-hand sources only — SEC filings, FDA and trial registries, wire releases. Latest issue below; all daily briefs →
Pharma Daily — October 5, 2026
One pipeline, five first-hand sources: 3 deals, 0 FDA approvals and 12 upcoming readouts, collected and charted without an LLM.